Zydus receives tentative approval from the USFDA for Bosentan Tablets for Oral Suspension

Zydus Lifesciences has announced that the company has received tentative approval from the United States Food and Drug Administration (USFDA) to market Bosentan Tablets for Oral Suspension, 32 mg, via an exchnage filing.

Bosentan Tablet for oral suspension is indicated for the treatment of pulmonary arterial hypertension (PAH) in pediatric patients aged 3 years and older with idiopathic or congenial PAH to improve pulmonary vascular resistance (PVR).

The drug will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad.

Bosentan Tablets for Oral Suspension had annual sales of USD 16 mn in the United States (IQVIA MAT Dec. 2022).

FPJ Shorts

Delhi: Metro Train Stops As Girl Runs On Track Near Rajendra Nagar Station In Alleged Suicide Attempt; Rescue VIDEO Goes Viral

'Allah Ka Shukar Hai': Reem Sameer Updates Fans About Her Tragic Accident (PHOTOS)

WATCH: Tauba Tauba Singer Karan Aujla Attacked By Fan With A Shoe During Live Concert In London

Ganesh Chaturthi 2024: Bollywood Celebs Arrive In Style At Shilpa Shetty House For Ganapati Bappa Darshan

The group now has 341 approvals and has so far filed over 440 ANDAs since th commencement of the filing process in FY 2003-04.

Read Also

Zydus receives tentative approval from the USFDA for Canagliflozin Tablets